UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Full-text)

Authors

  • Andrea Kokorovic Centre Hospitalier de l’Université de Montréal
  • Alan I. So Department of Urological Sciences, University of British Columbia
  • Hosam Serag Department of Urological Sciences, University of British Columbia
  • Christopher French Department of Surgery, Division of Urology, Memorial University
  • Robert J. Hamilton Division of Urology, Department of Surgery, Princess Margaret Cancer Centre
  • Jason P. Izard Department of Urology, Queen’s University
  • Jasmir G. Nayak Section of Urology, Department of Surgery, University of Manitoba
  • Frédéric Pouliot CHU de Quebec, Université Laval
  • Fred Saad Centre Hospitalier de l’Université de Montréal
  • Bobby Shayegan Division of Urology, Department of Surgery, McMaster University
  • Armen Aprikian McGill University Health Centre
  • Ricardo A. Rendon Department of Urology, Dalhousie University

DOI:

https://doi.org/10.5489/cuaj.8054

Keywords:

ADT, prostate cancer, side effects, CV, bone health

Downloads

Download data is not yet available.

Published

2022-07-21

How to Cite

Kokorovic, A. ., So, A. I., Serag, H. ., French, C. ., Hamilton, R. J. ., Izard, J. P. ., Nayak, J. G. ., Pouliot, F. ., Saad, F. ., Shayegan, B. ., Aprikian, A. ., & Rendon, R. A. . (2022). UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Full-text). Canadian Urological Association Journal, 16(8), E416–31. https://doi.org/10.5489/cuaj.8054

Issue

Section

CUA Guideline